Novo’s Wegovy to Be Offered Far More Widely on England’s NHS

Novo Nordisk launched the pill version of its blockbuster obesity drug Wegovy in the US this month. The oral formulation should broaden patient uptake versus the injectable, potentially meaningfully increasing Wegovy revenues and market share for Novo Nordisk and supporting the stock relative to peers in the obesity-treatment market.

Analysis

Novo Nordisk launched the pill version of its blockbuster obesity drug Wegovy in the US this month. The oral formulation should broaden patient uptake versus the injectable, potentially meaningfully increasing Wegovy revenues and market share for Novo Nordisk and supporting the stock relative to peers in the obesity-treatment market.